MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to detect drug and alcohol impairment in real time from short speech samples. The technology, which analyzes over 140 acoustic markers and is trained on more than 50 million data points, aims to provide a non-invasive alternative to traditional breath, saliva, urine, and laboratory-based testing.
The company plans to deploy its impairment detection system through Edge AI kiosks, with initial field testing scheduled for 2026. MindBio’s first commercial focus will be on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts.
MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers, and healthcare. The company’s proprietary research aims to address the increasing demand for faster, scalable workplace impairment detection. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice.
For more details, view the full article at https://ibn.fm/Gw5Fa. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
